77855-75-5

Usage

Uses

Used in Bioconjugation:
PEG5-(CH2CO2H)2 is used as a linker for bioconjugation to increase the solubility and stability of the conjugated biomolecules. The carboxylic acid groups can react with primary amine groups to form stable amide bonds, facilitating the attachment of various biomolecules, such as proteins, peptides, and drugs.
Used in Drug Delivery Systems:
In the pharmaceutical industry, PEG5-(CH2CO2H)2 is used as a component in drug delivery systems to improve the solubility, stability, and bioavailability of therapeutic agents. The PEG spacer and carboxylic acid groups can be utilized to attach drugs or other therapeutic agents to the PEG5-(CH2CO2H)2 molecule, enhancing their delivery and efficacy.
Used in Hydrogels:
In the biomedical field, PEG5-(CH2CO2H)2 is used as a component in hydrogel formulations. The hydrophilic PEG spacer and carboxylic acid groups can be crosslinked with other molecules to form hydrogels with tunable properties, suitable for various applications, such as tissue engineering, drug delivery, and wound healing.
Used in Surface Modification:
In materials science, PEG5-(CH2CO2H)2 is used for surface modification of various substrates, such as nanoparticles, polymers, and biomaterials. The PEG spacer and carboxylic acid groups can be used to attach PEG5-(CH2CO2H)2 to surfaces, providing improved biocompatibility, reduced protein adsorption, and enhanced stability.

Upstream product

• 112-60-7 Tetraethylene glycol 
• 79-08-3 bromoacetic acid 
• 211746-78-0 di-tert-butyl 3,6,9,12,15-pentaoxaheptadecanedioate 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain.

Homo-PROTACs: Bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation

E3 ubiquitin ligases are key enzymes within the ubiquitin proteasome system which catalyze the ubiquitination of proteins, targeting them for proteasomal degradation. E3 ligases are gaining importance as targets to small molecules, both for direct inhibition and to be hijacked to induce the degradation of non-native neo-substrates using bivalent compounds known as PROTACs (for 'proteolysis-targeting chimeras'). We describe Homo-PROTACs as an approach to dimerize an E3 ligase to trigger its suicide-type chemical knockdown inside cells. We provide proof-of-concept of Homo-PROTACs using diverse molecules composed of two instances of a ligand for the von Hippel-Lindau (VHL) E3 ligase. The most active compound, CM11, dimerizes VHL with high avidity in vitro and induces potent, rapid and proteasome-dependent self-degradation of VHL in different cell lines, in a highly isoform-selective fashion and without triggering a hypoxic response. This approach offers a novel chemical probe for selective VHL knockdown, and demonstrates the potential for a new modality of chemical intervention on E3 ligases.

MAGNETIC NANOSTRUCTURES AS THERANOSTIC AGENTS

The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use

Ligand Recognition by E- and P-Selectin: Chemoenzymatic Synthesis and Inhibitory Activity of Bivalent Sialyl Lewis x Derivatives and Sialyl Lewis x Carboxylic Acids

Described is the preparation of five sLex dimers and five sLex carboxylic acids by coupling chemoenzymatically synthesized amino-substituted sialyl Lewis x (sLex) derivative 4 to homobifunctional cross-linkers 20-24 of varying chain length. 20-24 were obtained by alkylating low-molecular-weight oligoethylene glycols with tert-butyl bromoacetate and subsequent transformation of the di-tert-butyl esters into disuccinimide esters. The products were assayed for inhibition against binding of a sLea-polymer to immobilized E- and P-selectin. In the E-selectin assay all dimers had lower IC50 values than the sLex monomer. The results show that comparable binding enhancements can be obtained with linkers of completely different length and rigidity. In the P-selectin assay four of the five sLex carboxylic acids displayed significantly improved inhibitory potency. The lowest IC50 value was observed for the compound with the shortest spacer between the sLex moiety and the additional carboxylate, being ca. 20-40 times more potent than unmodified sLex. These findings should be of importance for the design of new multivalent forms of sLex as well as sLex mimetics as high-affinity selectin ligands.